United States securities and exchange commission logo

                 May 2, 2022

       Mark Manfredi
       Chief Executive Officer
       Ikena Oncology, Inc.
       645 Summer Street, Suite 101
       Boston, MA 02210

                                                        Re: Ikena Oncology,
Statement on Form S-3
                                                            Filed April 27,
                                                            File No. 333-264517

       Dear Dr. Manfredi:

              This is to advise you that we have not reviewed and will not
review your registration

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

              Please contact Doris Stacey Gama at 202-551-3188 or Laura Crotty
at 202-551-7614 with
       any questions.


                 Division of Corporation Finance

                 Office of Life Sciences
       cc:                                              Stephanie Richards,